Committed to Innovation

Our clear focus on medical devices for minimally invasive treatment of valvular heart disease makes us experts.
We have a holistic approach based on our heritage in the design and development of unique technologies leveraging new advances in engineering. It is also based on our expertise in manufacturing and marketing such devices, and on our commitment to an Evidenced Based Medicine approach.
New Valve Technology stands for knowledge, experience, expertise and a pioneering spirit.  It is the distinctive sign of robust and practice-oriented R&D capabilities that pave the way for the creation of innovative medical technologies. Our aim is to place these innovations where they belong: in the hands of expert physicians.
Our current structural heart flagship product, the ALLEGRA™ transcatheter aortic valve implantation system, stemmed from this strong in-house R&D pipeline and manufacturing capabilities. It is a self-expanding supra-annular transcatheter aortic valve which presents unique design features and similar event rates compared to contemporary devices. It received CE mark in 2017 and further received CE approval for Valve-in-Valve indication on 29 April 2020.
We invest in shaping the future and we are committed to further validate our innovative technology through a comprehensive clinical program.

An overview of our clinical trials with the ALLEGRA™ TAVI system:

  • “First-In-Man” and “NAUTILUS” (CE approval studies)
  • “VIVALL” (extension for the valve-in-valve indication)
  • “FOLLOW” (post-market study)

Further information and the outcomes of our research will be available on this page soon.

11881-000-EN - Rev.04

CAUTION: Please note that the following pages are exclusively reserved for Health Care Professionals in countries with applicable health authority product registrations. To the extent this site contains information intended for use by licensed medical professionals, such materials are not intended to offer professional medical advice. Prior to use, please consult device labeling for prescriptive information and operating instructions. Please contact your Biosensors International representative for availability or the products and registration status.

The law restricts these devices to sale by or on the order of a physician. Prior to use, it is important to read the "Instructions for Use" supplied with these devices for indications, contraindications, suggested procedures, warnings, and precautions.

Biosensors’ interventional cardiology products, including BioMatrix NeoFlex™, BioMatrix™ Alpha, BioFreedom™, BioFreedom™ Ultra, BMX-J® and RISE™ NC, are not available for sale in the United States and certain other countries. ALLEGRA™ is a product of NVT GmbH. Blue Sail Medical Co., Ltd is the ultimate parent company of NVT GmbH and Biosensors International Group, Ltd. and its subsidiaries are collaborating for the commercialization of the ALLEGRA™ device.

BioMatrix NeoFlex, BioMatrix Alpha, BioFreedom, BioFreedom Ultra, BMX-J, Juno, S-Stent and Rise NC are trademarks or registered trademarks of Biosensors International Group, Ltd. ALLEGRA is a trademark or registered trademark of NVT AG. All other cited trademarks are the property of their respective owners.